Differentiated thyroid cancer: no RFS benefits for retreatment with adjuvant radioactive iodine

  • Bouvet C & al.
  • Front Endocrinol (Lausanne)
  • 1 Jan 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant radioactive iodine (RAI) is not associated with improved recurrence-free survival (RFS) in patients with differentiated thyroid cancer (DTC) initially treated with total thyroidectomy and RAI and subsequently treated with additional surgery for locally persistent or recurrent disease.

Why this matters

  • The role of adjuvant RAI after reoperation is controversial.

Key results

  • 36.5% of patients experienced disease recurrence after retreatment (median RFS, 15.9 years).
  • Age >55 years was associated with reduced RFS in multivariate analysis (HR, 3.9; P<.00001>
  • Receipt of adjuvant RAI was not significantly associated with RFS (P=.11); similar results were observed after propensity-score matching (P=.54).

Study design

  • 85 patients with locally persistent/recurrent DTC, 58% who were retreated with reoperation and adjuvant RAI and 42% only with reoperation, were analyzed for RFS outcomes and associated factors.
  • Funding: None disclosed.

Limitations

  • Retrospective study design.
  • Small patient sample size.